The past decade in biological research might well be christened the age of CRISPR, a once-curious feature of bacterial genomes that spawned a handy tool for editing genes. Using CRISPR-based tools, researchers are making leaps in basic clinical research, and biotechnology companies are racing to launch trials of gene therapies for an array of diseases. Yet the immediate gains from this game-changing technique might spring from its application to agriculture. Hornless dairy cattle, drought-resistant wheat, and nonbrowning mushrooms are merely the harbingers of an approaching agricultural revolution, says Rodolphe Barrangou, a molecular biologist and food scientist at North Carolina State University. Barrangou's foresight stems from his long familiarity with CRISPR. More than a decade ago, while working at the Danish food ingredient manufacturer Danisco (now DuPont), Barrangou furnished experimental proof for the notion that CRISPR confers a form of adaptive immunity that helps bacteria fend off invading viruses. For this crucial insight into the fundamental biology of CRISPR, Barrangou was honored with 2017 National Academy of Sciences Award in molecular biology. PNAS spoke to Barrangou about his wide-ranging work on CRISPR.
PNAS: CRISPR entered the spotlight when its potential as a genome editor became apparent, but your tryst with it began more than a decade ago while working with Philippe Horvath in the food industry. Those efforts led to a milestone 2007 article in Science, in which you demonstrated that bacteria use CRISPR-Cas systems as a form of adaptive immunity against viruses (1). Could you take our readers down memory lane?
Barrangou: For a long time, people didn't really have a clue what these repeated DNA sequences-the CRISPR arrays-in bacterial genomes did. Around 2005, three different groups almost concurrently found similarities between viral sequences and these repeats and spacers in bacterial genomes. Already by this time, Philippe and I had been using CRISPR to genotype bacteria; these repeats and spacers were so distinctive that they could be used to distinguish closely related strains of bacteria within the same species. Meanwhile, we were also sequencing the genomes of hundreds of bacteria commonly used as starter cultures in the dairy industry to make yogurt and cheese. We noticed that the assembly of these genome sequences was hampered by the CRISPR arrays. As we were simultaneously sequencing the bacteriophages that infect and destroy dairy cultures, just as others had observed at the same time, we saw that the sequences that hampered our genome assembly, the repeat-associated spacers, matched those of the bacteriophages. We went back and sequenced strains of dairy bacteria from different times in the past (some of those strains were made at DuPont), and we saw that the genomes were evolving over time. The strains had picked up sequences from bacteriophage genomes to which they were exposed, representing a form of bacterial adaptive immunity. We also showed in the Science article that we can engineer this immunity by adding or removing spacers, and that the immunity depends on the bacterial cas9 gene (1).
are natural ways to harness CRISPR immunity, and this is now common practice in the dairy industry. Phage infection is a major concern in the dairy industry. So you select bacterial strains that make the best yogurt, expose them to phages, screen for strains that become naturally vaccinated against the phages, and repeat the exposure and screening until you end up with a strain that is immune to a diversity of common phages. This can be achieved in a matter of weeks. Since 2011, DuPont yogurt and cheese cultures have been naturally enhanced in this way using CRISPR immunity; so many people are likely to have consumed a product that was manufactured using CRISPRenhanced starter cultures.
PNAS: Your early work on CRISPR was for genotyping bacteria, and you have used CRISPR to track foodborne pathogens and outbreaks. Could you explain how CRISPR can enable epidemic surveillance?
Barrangou: The vintage application of CRISPR was in fact for genotyping bacteria. Over the past 12 years, we have used CRISPR-based genotyping in a range of pathogens, such as Escherichia coli, Clostridium difficile, Pseudomonas, Salmonella, and others. The genotyping provides a sort of vaccination card for individual bacteria that were exposed to phages over time. Most CRISPR loci are in the range of 20-100 spacers accumulated over thousands of years (in exceptional cases, they grow particularly long, up to 587 vaccination events, for example). So you can create a CRISPR-based map of this history and overlay the map with other diseaserelated information to track outbreaks. Years ago, working with the FDA [Food and Drug Administration] and CDC [Centers for Disease Control and Prevention], we used this method to investigate outbreaks of Salmonella in spinach in the United States. We have also used this method to genotype Salmonella on different farms in Wisconsin as well as for tracking cheese and yogurt cultures in the industry.
PNAS:
Extending those applications, CRISPR can also be used to develop next-generation antibiotics. What is the scientific basis of this subversive strategy?
Barrangou: Given the widespread issue of antibiotic resistance, there is a need for highly specific, smart antibiotics. We and our colleagues have shown that we can harness CRISPR to selectively target and kill bacteria by choosing the right Cas enzyme and exploiting the lack of DNA repair pathways in bacteria [without the repair pathways, which are central to the genome editing function of CRISPR, cuts to the DNA can result in bacterial cell death]. We are now developing such CRISPR-based antibiotics, which are not yet commercialized, to target antibiotic-resistant bacteria such as the carbapenem-resistant Enterobacteriacea [some of which fend off most available antibiotics]. There are no clinical trials planned yet, but we are hoping to launch them in 2018. We started out using CRISPR to rid bacteria of phages in the dairy industry, so there is some irony in using CRISPR to target bacteria.
Since the original demonstration of CRISPR as a genome editing tool, the toolbox has rapidly evolved. Among a raft of upgrades, for example, is the development of Cas13b, an RNA-guided enzyme that cleaves RNA, instead of DNA, and that could allow researchers to tweak gene expression without touching the genome. What in your opinion are the major technical hurdles currently facing the use of CRISPR in genome editing?
Barrangou: After the initial hand-wringing on offtarget cutting, the focus now is on controlling endogenous repair pathways to ensure desired edits. The other major hurdle concerns methods of delivering the genome editing tool to desired tissues in a consistent fashion. Delivery is part of the reason why leading CRISPR companies have thus far largely focused on diseases in which delivery has already been worked out: liver disease, eye diseases, blood diseases, muscle disorders, etc. But for other tissues, say lungs or brain, we still don't have the technology to deliver the tool to every single cell within the tissue.
PNAS: CRISPR has started to influence agriculture. What aspects of livestock production are likely to be influenced in the near future?
Barrangou: From a livestock standpoint, the big three would be poultry, pork, and cattle. Breeders are now aware of the advantages of CRISPR, and it is certainly being implemented at the [laboratory] scale. It has not been commercialized yet, but many industrial livestock breeders with an R&D [research and development] unit now have a CRISPR program focused on goals such as optimizing yield. You can think of the examples of genome-edited plants and animals reported in the news media-the white button mushrooms, droughtresistant corn, hornless cattle-as pilot projects launched to test the market, regulatory landscape, and public response to genome-edited crops and animals; there are several other such projects underway.
With the NAS award in molecular biology, you have joined a roster of heavyweights that includes many who went on to win coveted honors and some whose names are commonplace in biology textbooks. How do you feel about receiving the award?
Barrangou: It's a great honor to receive an award that has previously gone to such distinguished and highly regarded scientists. I was thrilled to accept the award on behalf of all of the colleagues I have worked with in the past. Recognition by the NAS is a tremendous honor.
